Celldex Therapeutics, Inc. (NASDAQ:CLDX) fell 6.5% during mid-day trading on Monday . The company traded as low as $0.43 and last traded at $0.43. 1,337,211 shares changed hands during trading, a decline of 43% from the average session volume of 2,357,688 shares. The stock had previously closed at $0.46.

A number of brokerages have issued reports on CLDX. HC Wainwright set a $2.00 price objective on shares of Celldex Therapeutics and gave the company a “buy” rating in a report on Thursday, August 9th. Jefferies Financial Group reaffirmed a “hold” rating on shares of Celldex Therapeutics in a report on Friday, August 10th. Zacks Investment Research lowered shares of Celldex Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, July 3rd. ValuEngine raised shares of Celldex Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, June 1st. Finally, Cowen reaffirmed a “hold” rating on shares of Celldex Therapeutics in a report on Thursday, August 9th. One research analyst has rated the stock with a sell rating, six have given a hold rating and two have given a buy rating to the company. Celldex Therapeutics currently has a consensus rating of “Hold” and an average target price of $3.75.

The firm has a market cap of $74.82 million, a price-to-earnings ratio of -0.56 and a beta of 2.55.

Celldex Therapeutics (NASDAQ:CLDX) last posted its earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.03. Celldex Therapeutics had a negative net margin of 1,159.26% and a negative return on equity of 47.40%. The firm had revenue of $2.76 million during the quarter, compared to analyst estimates of $2.70 million. equities analysts predict that Celldex Therapeutics, Inc. will post -0.44 EPS for the current fiscal year.

Several hedge funds have recently bought and sold shares of the stock. BlackRock Inc. grew its holdings in shares of Celldex Therapeutics by 1.7% in the first quarter. BlackRock Inc. now owns 10,097,481 shares of the biopharmaceutical company’s stock valued at $23,527,000 after purchasing an additional 166,780 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Celldex Therapeutics by 2,633.4% in the second quarter. Renaissance Technologies LLC now owns 4,220,687 shares of the biopharmaceutical company’s stock valued at $2,126,000 after purchasing an additional 4,066,273 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Celldex Therapeutics by 74.8% in the first quarter. Dimensional Fund Advisors LP now owns 4,167,585 shares of the biopharmaceutical company’s stock valued at $9,710,000 after purchasing an additional 1,783,765 shares in the last quarter. TSP Capital Management Group LLC grew its holdings in shares of Celldex Therapeutics by 12.4% in the first quarter. TSP Capital Management Group LLC now owns 1,436,957 shares of the biopharmaceutical company’s stock valued at $3,348,000 after purchasing an additional 158,900 shares in the last quarter. Finally, Acadian Asset Management LLC lifted its position in Celldex Therapeutics by 378.4% in the second quarter. Acadian Asset Management LLC now owns 1,157,880 shares of the biopharmaceutical company’s stock worth $583,000 after buying an additional 915,863 shares during the last quarter. 33.54% of the stock is owned by hedge funds and other institutional investors.

Celldex Therapeutics Company Profile (NASDAQ:CLDX)

Celldex Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of various immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer; and CDX-3379, a human monoclonal antibody that is in Phase II study in combination with cetuximab for the treatment of head and neck squamous cell carcinoma.

Read More: What is a Leveraged Buyout (LBO)?

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.